Journal
ISCIENCE
Volume 24, Issue 9, Pages -Publisher
CELL PRESS
DOI: 10.1016/j.isci.2021.103014
Keywords
-
Categories
Funding
- University of Pittsburgh Medical Center Aging Institute pilot fund
- National Institutes of Health [1R35GM137905, R01-GM097082, R01HL137709]
- Israeli Science Foundation [1466/18]
- Israel Ministry of Science and Technology
Ask authors/readers for more resources
Researchers developed a Nb-HSA nanobody that can be fused to small biologics to extend half-life, significantly prolonging the half-lives of Nb(HSA)s and finding that their pharmacokinetics positively correlate with their albumin binding affinities at endosomal pH.
Therapeutic and diagnostic efficacies of small biomolecules and chemical compounds are hampered by suboptimal pharmacokinetics. Here, we developed a repertoire of robust and high-affinity antihuman serum albumin nanobodies (Nb-HSA) that can be readily fused to small biologics for half-life extension. We characterized the thermostability, binding kinetics, and cross-species reactivity of Nb(HSA)s, mapped their epitopes, and structurally resolved a tetrameric HSA-Nb complex. We parallelly determined the half-lives of a cohort of selected Nb(HSA)s in an HSA mouse model by quantitative proteomics. Compared to short-lived control nanobodies, the half-lives of Nb(HSA)s were drastically prolonged by 771-fold. Nb(HSA)s have distinct and diverse pharmacokinetics, positively correlating with their albumin binding affinities at the endosomal pH. We then generated stable and highly bioactive Nb-HSA-cytokine fusion constructs Duraleukin'' and demonstrated Duraleukin's high preclinical efficacy for cancer treatment in a melanoma model. This high-quality and versatile Nb toolkit will help tailor drug half-life to specific medical needs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available